#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	17336	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2458	865.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1817	1817	T	1122	T,G	1121,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	17336	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2458	865.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1551	1551	C	1082	C,T,A	1080,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29206	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4080	891.8	0	.	n	.	0	C543T	SNP	543	543	C	1211	1211	T	1128	T	1128	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29206	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4080	891.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	2005	2005	A	1178	A,C	1177,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29206	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4080	891.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2639	2639	C	960	C,A	959,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29206	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4080	891.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2713	2713	A	919	A,G	918,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29206	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4080	891.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3265	3265	C	1074	C,A,T,G	1069,1,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2582	folP	855	855	99.88	folP.l15.c4.ctg.1	1866	172.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1174	1176	AGC	256;260;256	A;G;C,G	256;260;255,1	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	6258	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3941	197.9	0	.	p	.	0	V290I	NONSYN	868	870	GTT	1454	1456	ATT	239;240;238	A,C;T;T,G	238,1;240;236,2	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	6258	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3941	197.9	1	SNP	p	S91F	0	.	.	271	273	TCC	857	859	TCC	206;205;204	T,G;C,T;C	205,1;204,1;204	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	6258	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3941	197.9	1	SNP	p	D95N	0	.	.	283	285	GAC	869	871	GAC	225;226;227	G;A,G,C;C	225;224,1,1;227	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	6258	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3941	197.9	1	SNP	p	D95G	0	.	.	283	285	GAC	869	871	GAC	225;226;227	G;A,G,C;C	225;224,1,1;227	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	2402	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1808	165.4	1	SNP	p	G45D	1	.	.	133	135	GAC	643	645	GAC	296;297;302	G;A,G;C	296;296,1;302	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1382	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1493	115.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	213.5	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1827	1829	GCA	274;272;269	G;C;A	274;272;269	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	213.5	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2310	2312	ATT	276;280;278	A,T,C;T,A;T	274,1,1;279,1;278	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	213.5	1	SNP	p	D86N	0	.	.	256	258	GAC	780	782	GAC	261;263;263	G;A;C	261;263;263	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	213.5	1	SNP	p	S87I	0	.	.	259	261	AGT	783	785	AGT	262;262;260	A,C;G;T	261,1;262;260	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	213.5	1	SNP	p	S87R	0	.	.	259	261	AGT	783	785	AGT	262;262;260	A,C;G;T	261,1;262;260	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	213.5	1	SNP	p	S87W	0	.	.	259	261	AGT	783	785	AGT	262;262;260	A,C;G;T	261,1;262;260	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5778	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3373	213.5	1	SNP	p	S88P	0	.	.	262	264	TCC	786	788	TCC	261;260;260	T,G;C;C	260,1;260;260	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5146	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3164	202.5	0	.	p	.	0	H611N	NONSYN	1831	1833	CAC	2411	2413	AAC	262;263;263	A,T;A,G,T;C	261,1;261,1,1;263	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5146	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3164	202.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1808	1810	GGC	262;260;259	G;G;C	262;260;259	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	A438V	NONSYN	1312	1314	GCA	1908	1910	GTC	246;246;246	G,T,A;T,C;C,A	244,1,1;245,1;245,1	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	V444E	NONSYN	1330	1332	GTT	1926	1928	GAA	244;244;243	G,T;A,T;A,T	243,1;243,1;242,1	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	L448V	NONSYN	1342	1344	CTC	1938	1940	GTC	245;243;244	G,C;T;C	244,1;243;244	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	Q458K	NONSYN	1372	1374	CAA	1968	1970	AAA	263;265;265	A,C;A,C;A,G	262,1;263,2;264,1	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	I462V	NONSYN	1384	1386	ATA	1980	1982	GTC	268;266;267	G,A;T,G;C,A	267,1;265,1;266,1	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	F463I	NONSYN	1387	1389	TTC	1983	1985	ATC	267;267;268	A,T,C;TCA,T;C	265,1,1;262,1;268	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	E465A	NONSYN	1393	1395	GAA	1989	1991	GCC	272;270;271	G;C;C	272;270;271	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	R469K	NONSYN	1405	1407	CGC	2001	2003	AAA	274;275;276	A;A;A,C	274;275;275,1	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	E470K	NONSYN	1408	1410	GAG	2004	2006	AAA	276;278;277	A,C;A;A	274,2;278;277	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	N473E	NONSYN	1417	1419	AAT	2013	2015	GAG	275;274;274	G,T;A;G,A	273,2;274;273,1	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	N513Y	NONSYN	1537	1539	AAC	2133	2135	TAC	217;217;218	T;A;C	217;217;218	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	G517A	NONSYN	1549	1551	GGT	2145	2147	GCC	222;220;219	G;C;C,G	222;220;218,1	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	0	.	p	.	0	A550T	NONSYN	1648	1650	GCA	2244	2246	ACA	219;221;225	A;C;A	219;221;225	.	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1527	1529	GCA	271;273;270	G;C,G;A,C	271;272,1;269,1	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1530	1532	ATC	269;271;270	A,C;T,A;C	268,1;270,1;270	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1542	1544	GTG	275;279;281	G;T;G,A	275;279;280,1	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1542	1544	GTG	275;279;281	G;T;G,A	275;279;280,1	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2100	2102	GCG	250;253;255	G,T,A;C,G,A;G,T,A	248,1,1;248,4,1;253,1,1	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2100	2102	GCG	250;253;255	G,T,A;C,G,A;G,T,A	248,1,1;248,4,1;253,1,1	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2223	2225	GGT	212;211;212	G;G;T,G	212;211;210,2	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2232	2234	GGC	211;211;210	G,T;G;C	209,2;211;210	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	4694	penA	1752	1752	95.66	penA.l15.c4.ctg.1	2939	198.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2250	2252	CCG	238;239;241	C;C;G,T	238;239;240,1	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6666	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3466	239.6	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1817	1819	CTG	248;249;253	C,A;T,C;G	247,1;248,1;253	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3012	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2275	165.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	835	835	C	230	C	230	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.71	porB1a.l15.c4.ctg.2	361	40.2	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	36;37;39	T;T;A	36;37;39	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.71	porB1a.l15.c4.ctg.2	361	40.2	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	79;79;79	C;A;T	79;79;79	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.71	porB1a.l15.c4.ctg.2	361	40.2	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	79;79;79	A;G;T	79;79;79	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.71	porB1a.l15.c4.ctg.2	361	40.2	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	79;79;79	T,C;A;C	78,1;79;79	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.71	porB1a.l15.c4.ctg.2	361	40.2	0	.	p	.	0	R307E	NONSYN	919	921	AGA	161	163	GAA	4;4;4	G;A;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.71	porB1a.l15.c4.ctg.2	361	40.2	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	4;4;4	G;C;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.71	porB1a.l15.c4.ctg.2	361	40.2	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	5;5;5	A;T;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.71	porB1a.l15.c4.ctg.2	361	40.2	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	5;5;5	T;C;G	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.71	porB1a.l15.c4.ctg.2	361	40.2	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	5;5;5	G;C;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.71	porB1a.l15.c4.ctg.2	361	40.2	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	5;5;5	A;G;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.71	porB1a.l15.c4.ctg.2	361	40.2	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	5;5;5	G;C;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.71	porB1a.l15.c4.ctg.2	361	40.2	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	6;6;5	G;T;T	6;6;5	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3446	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1799	235.7	0	.	p	.	0	R143G	NONSYN	427	429	AGA	879	881	GGA	259;255;258	G,A;G,A;A,G,C	258,1;253,1;256,1,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3446	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1799	235.7	0	.	p	.	0	.	INDELS	629	630	AA	1082	1084	TAG	289;294;293	T;A;G	288;293;292	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3446	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1799	235.7	0	.	p	.	0	.	MULTIPLE	631	633	TAC	1086	1089	CAAT	291;291;290;288	C;A;A,T;T,C	291;291;289,1;287,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3446	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1799	235.7	0	.	p	.	0	N212fs	FSHIFT	634	634	A	1091	1091	T	283	T	283	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3446	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1799	235.7	1	SNP	p	G120K	0	.	.	358	360	GGT	810	812	GGT	282;283;280	G,C,A;G;T,G,A	280,1,1;283;278,1,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3446	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1799	235.7	1	SNP	p	A121D	0	.	.	361	363	GCC	813	815	GCC	280;281;282	G;C;C	280;281;282	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3446	porB1b	1035	1035	98.85	porB1b.l15.c17.ctg.1	1799	235.7	1	SNP	p	A121N	0	.	.	361	363	GCC	813	815	GCC	280;281;282	G;C;C	280;281;282	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	12084	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5282	285.1	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2206	2208	CAT	299;301;302	C,T;A,C;T	297,2;300,1;302	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1702	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1422	149.0	1	SNP	p	V57M	0	.	.	169	171	GTG	683	685	GTG	307;307;307	G;T;G	307;307;307	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
